Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular disease, will present at the 10 th Annual JMP Securities Research Conference in San Francisco on Tuesday, May 10, 2011. President and Chief Executive Officer David L. Martin and Chief Financial Officer Laurence L. Betterley will provide an overview of the company and its initiatives.


10th Annual JMP Securities Research Conference
Tuesday, May 10; 1:30 p.m. PT
The Ritz-Carlton
San Francisco


To listen to a live webcast of the presentation, go to the investor information section of the company’s website,, and click on the webcast icon.
If you have any difficulty accessing the webcast, please contact

Mick Forgey: (612) 455-1789;

About Cardiovascular Systems, Inc.Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360 ® and Diamondback Predator 360 ® Orbital PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 46,000 PAD procedures have been performed using the Diamondback 360° in leading institutions across the United States.

CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its Diamondback 360° System in treating coronary arteries. The coronary system is under clinical investigation and is currently not commercially available in the United States.

For more information, visit the company’s website at

Copyright Business Wire 2010